BIA 10-2474: Some Lessons are Clear but Important Questions Remain Unanswered

Richard W Peck¹, Sarah A Holstein², Piet H van der Graaf^{3

4}

Affiliations

¹ Pharma Research and Development, Roche Innovation Center Basel, Basel, Switzerland.
² Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
³ Certara, Canterbury, UK.
⁴ Leiden University, Leiden, The Netherlands.

Editorial

Richard W Peck et al. Clin Pharmacol Ther. 2022 Feb.

. 2022 Feb;111(2):343-345.

doi: 10.1002/cpt.2495.

Richard W Peck¹, Sarah A Holstein², Piet H van der Graaf^{3

4}

¹ Pharma Research and Development, Roche Innovation Center Basel, Basel, Switzerland.
² Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
³ Certara, Canterbury, UK.
⁴ Leiden University, Leiden, The Netherlands.

No abstract available

Comment on

Safety, Tolerability, and Pharmacokinetics of FAAH Inhibitor BIA 10-2474: A Double-Blind, Randomized, Placebo-Controlled Study in Healthy Volunteers.
Rocha JF, Santos A, Gama H, Moser P, Falcão A, Pressman P, Wallace Hayes A, Soares-da-Silva P. Rocha JF, et al. Clin Pharmacol Ther. 2022 Feb;111(2):391-403. doi: 10.1002/cpt.2290. Epub 2021 Jun 24. Clin Pharmacol Ther. 2022. PMID: 33998672 Free PMC article. Clinical Trial.

1. Sibille, M., Donazzolo, Y., Lecoz, F. & Krupka, E. After the London tragedy is it still possible to consider phase I is safe? Br. J. Clin. Pharmacol. 62, 502-503 (2006).
1. Rocha, J.F. et al. Safety, tolerability, and pharmacokinetics of FAAH inhibitor BIA 10-2474: a double-blind, randomized, placebo-controlled study in healthy volunteers. Clin. Pharmacol. Ther. 111, 391-403 (2022).
1. Cohen, A., van Smeden, J. & Webb, D.J. De-risking clinical trials: The BIAL phase I trial in foresight. Clin. Pharmacol. Ther. 111, 362-365 (2022).
1. Kerbrat, A. et al. Acute neurological disorder from an inhibitor of fatty acid amide hydrolase. N. Eng. J. Med. 375, 1717-1725 (2016).
1. Report by the Temporary Specialist Scientific Committee (TSSC). "FAAH (Fatty Acid Amide Hydrolase)", on the causes of the accident during a Phase 1 clinical trial in Rennes in January 2016 <https://archiveansm.integra.fr/var/ansm_site/storage/original/applicatio.... Accessed November 16, 2021.